Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$468M |
| 2 |
Johnson & Johnson
JNJ
|
+$440M |
| 3 |
IBM
IBM
|
+$355M |
| 4 |
Booking.com
BKNG
|
+$332M |
| 5 |
RAI
Reynolds American Inc
RAI
|
+$331M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LLTC
Linear Technology Corp
LLTC
|
+$482M |
| 2 |
Walt Disney
DIS
|
+$247M |
| 3 |
Visa
V
|
+$219M |
| 4 |
Deere & Co
DE
|
+$200M |
| 5 |
Johnson Controls International
JCI
|
+$179M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.02% |
| 2 | Technology | 13.31% |
| 3 | Financials | 12.25% |
| 4 | Industrials | 9.65% |
| 5 | Consumer Staples | 9.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVLN
2226
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $2.04M | ﹤0.01% |
190,110
-142,760
| -43% | -$1.46M |
|
|
SHLO
2227
DELISTED
Shiloh Industries Inc
SHLO
| $2.04M | ﹤0.01% |
149,700
+124,100
| +485% | +$1.55M |
|
|
JCAP
2228
DELISTED
Jernigan Capital, Inc.
JCAP
| $2.04M | ﹤0.01% |
88,400
-2,800
| -3% | -$60.6K |
|
2229
Universal Electronics
UEIC
$66.6M
| $2.04M | ﹤0.01% |
+29,723
| New | +$1.96M |
|
|
GPP
2230
DELISTED
Green Plains Partners LP
GPP
| $2.03M | ﹤0.01% |
100,981
-26,903
| -21% | -$537K |
|
2231
Ascent Industries
ACNT
$134M
| $2.02M | ﹤0.01% |
164,800
-8,900
| -5% | -$101K |
|
|
ENV
2232
DELISTED
ENVESTNET, INC.
ENV
| $2.02M | ﹤0.01% |
+62,492
| New | +$2.27M |
|
2233
Matsons
MATX
$6.39B
| $2.02M | ﹤0.01% |
+63,500
| New | +$2.18M |
|
2234
Evolent Health
EVH
$527M
| $2.01M | ﹤0.01% |
90,300
+49,200
| +120% | +$944K |
|
|
CDMO
2235
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $2.01M | ﹤0.01% |
439,665
+86,258
| +24% | +$289K |
|
|
NWY
2236
DELISTED
New York & Co Inc
NWY
| $2.01M | ﹤0.01% |
1,029,500
+61,700
| +6% | +$136K |
|
2237
Valvoline
VVV
$4.31B
| $2.01M | ﹤0.01% |
+81,753
| New | +$1.87M |
|
2238
Aegon
AEG
$13.9B
| $2M | ﹤0.01% |
507,813
+135,842
| +37% | +$576K |
|
|
REGI
2239
DELISTED
Renewable Energy Group, Inc.
REGI
| $2M | ﹤0.01% |
191,027
-460,000
| -71% | -$4.25M |
|
2240
Genco Shipping & Trading
GNK
$1.13B
| $1.99M | ﹤0.01% |
+159,130
| New | +$1.65M |
|
2241
DXP Enterprises
DXPE
$3B
| $1.98M | ﹤0.01% |
52,300
+31,100
| +147% | +$1.11M |
|
|
BOXC
2242
DELISTED
Brookfield Can Office Properties
BOXC
| $1.98M | ﹤0.01% |
84,100
+48,100
| +134% | +$1.1M |
|
2243
Farmers National Banc Corp
FMNB
$970M
| $1.98M | ﹤0.01% |
137,700
-15,900
| -10% | -$218K |
|
|
CMRX
2244
DELISTED
Chimerix, Inc.
CMRX
| $1.98M | ﹤0.01% |
+309,609
| New | +$1.76M |
|
|
EPZM
2245
DELISTED
Epizyme, Inc
EPZM
| $1.98M | ﹤0.01% |
+115,188
| New | +$1.53M |
|
2246
Lazard
LAZ
$4.43B
| $1.97M | ﹤0.01% |
42,800
-426,700
| -91% | -$18.4M |
|
|
MSON
2247
DELISTED
Misonix Inc
MSON
| $1.97M | ﹤0.01% |
166,600
-2,300
| -1% | -$24.9K |
|
2248
Federated Hermes
FHI
$4.74B
| $1.97M | ﹤0.01% |
74,600
-423,700
| -85% | -$11.3M |
|
2249
Identive
INVE
$64.1M
| $1.97M | ﹤0.01% |
278,359
+43,419
| +18% | +$214K |
|
|
CVLY
2250
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $1.96M | ﹤0.01% |
87,714
-9,493
| -10% | -$217K |
|
Similar funds
Jim Simons's Q1 2017 Portfolio in Review
As of Q1 2017, Jim Simons held 3,652 positions worth $71.6B, up 13% from $63.2B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Jim Simons deployed $5.19B of net new capital in Q1 2017, opening 433 new positions and adding to 1,585 existing holdings. Its largest new stake was Merck: 7,716,460 shares worth $468M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Walt Disney, an estimated $247M trimmed.
- Jim Simons's largest Q1 2017 buy was Merck: 7,716,460 shares worth $468M.
- Jim Simons added most to Johnson & Johnson in Q1 2017, an estimated $440M increase.
- Jim Simons's biggest Q1 2017 reduction was Walt Disney, cutting an estimated $247M.
- Jim Simons fully exited Linear Technology Corp in Q1 2017, selling an estimated $482M.
- Jim Simons's ten largest holdings make up 7.9% of its $71.6B portfolio in Q1 2017.
- Jim Simons opened 433 new positions and closed 462 in Q1 2017.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $71.6B.
Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.